For years, conventional wisdom held that skin improvements among patients on GLP-1 medications were a byproduct of weight loss, which reduces inflammation. But doctors are spotting a much more complex reality — and new research supports their observations.

At the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, Pennsylvania, dermatologist Joe K. Tung, MD, MBA, noticed dramatic changes in his patients with psoriasis just starting a GLP-1. Their plaques began “melting away” within 2 days. “That’s too fast for that to be a weight-loss effect,” he said. “The next step for me was just thinking, could this mechanistically be plausible?”

Curious, he started digging through past research. He found himself looking back at a 2011 paper that first linked GLP-1s to an anti-inflammatory response in immune cells (T cells) in the skin lesions of two patients with psoriasis and with type 2 diabetes. Tung’s own research, published last year, showed that GLP-1 therapy might lower the risk of developing psoriasis and hidradenitis suppurativa (HS; a chronic inflammatory skin condition) in patients with type 2 diabetes.

But as researchers look closer, it turns out that’s just scratching the surface.

Beyond Weight Loss: A Direct Link

Psoriasis is leading the charge in this new territory, showing an intriguing overlap between GLP-1 receptors and immune cells in the skin.

Ravi Ramessur, MD, PhD, a postdoctoral research fellow at the University of Pennsylvania in Philadelphia, recently led an analysis looking at genetics. The study showed that people genetically predisposed to have more active GLP-1 receptors had a significantly lower risk of developing psoriasis and psoriatic arthritis — even after accounting for the effects of body fat. In fact, Ramessur has seen several patients with psoriasis experience almost completely clear skin on GLP-1 therapy alone.

Because of this, researchers are shifting their focus. The question is no longer whether GLP-1s help the skin simply because patients lose weight.

“The question now is, ‘With the receptor in the skin, is the GLP-1 itself doing something directly in the skin with inflammation, independent of its effect on weight?’” Tung said. “That’s what’s most exciting. That’s what the field is talking about most.”

Rethinking the Role of Fat in Skin Disease

Recent data backs up these real-world observations of rapid or complete plaque clearance from GLP-1s. Earlier this year, data showed that combining a standard psoriasis drug (the IL-17 inhibitor ixekizumab) with the weight-loss medication tirzepatide outperformed the psoriasis drug alone for adults with overweight or obesity. The patients saw significantly better skin outcomes.

There is now so much early evidence linking GLP-1s to inflammatory skin conditions that the science is filling up major medical reviews. It marks a massive shift in how doctors view the skin. As recently as two decades ago, medical schools still taught that the skin had three main layers, and fat tissue had nothing to do with skin disease. The field of dermatology has spent the past 20 years overturning that idea, learning how full-body inflammation drives skin conditions.

“In the past couple years, obesity has really reframed that conversation again because we know fat is also an active inflammatory organ, not just a place to store energy,” said Tung, who is also the medical director of UPMC’s outpatient dermatology clinic. “So when a psoriasis or HS patient gains weight, you’re not just adding that comorbid condition, you’re also feeding and fueling that same inflammatory fire.” 

What Other Skin Issues Can GLP-1s Target?

In addition to psoriasis, evidence has mounted for GLP-1 impacts on:

• HS. Early data are mostly observational, but it suggests GLP-1s can help reduce painful, fluid-filled lumps and regulate oil glands. Beyond the metabolic benefits, Ramessur noted a practical perk: HS often flares up in skin folds like the armpits and groin. Frictional irritation in these areas can worsen symptoms, so weight loss helps physically ease the burden. “I think it’s very promising that it may feasibly have benefit on disease severity in HS or even avoiding the disease itself,” he said.
• Atopic dermatitis. One observational study found that patients on GLP-1s needed fewer corticosteroids, suggesting the medications might treat underlying metabolic triggers, like gut inflammation. However, other studies show mixed results — Ramessur’s genetic analysis did not find this same link.
• Wound healing. Several early studies suggest GLP-1s may speed up how fast wounds heal. “Wound healing is probably the most underappreciated part of this GLP story,” Tung said. “It doesn’t get talked about as much, but biologically, it’s pretty clean because wound healing doesn’t rely on the weight-loss pathway at all.”

The Next Frontier: Head-to-Head Trials

All this early data gives researchers plenty of material to work with. But the unwritten chapters in this story belong to clinical trials that test GLP-1s entirely on their own for skin health, rather than alongside other drugs or strictly for weight loss.

Psoriasis is the clear frontrunner for these future studies.

“There are still unanswered questions as to other conditions where obesity is a big problem, like HS, and whether there’s benefit there,” Ramessur said. “We’re moving toward clinical trials using just GLP-1s to help answer that.”

The experts cited in this article had no relevant financial disclosures.